ReviewThe Journal of molecular diagnostics : JMD2006
Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.
Review in The Journal of molecular diagnostics : JMD, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 85 citations in OpenAlex.
- Systemic Mastocytosis in Adults: 2026 Update on Diagnosis, Risk Stratification and Management.American journal of hematology · 2026Review
- New insight into role of mast cells in erythrocyte homeostasis and clearance under oxidative stress conditionsBiochemistry and biophysics reports · 2026Article
- Mastocytosis.Nature reviews. Disease primers · 2025Review
- Systemic mastocytosis, in the context of a deleterious germlineJAAD case reports · 2023Article
- Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update.Cancers · 2022Review
- Efficacy of Omalizumab in Indolent Systemic Mastocytosis.Case reports in hematology · 2019Article
- Impact of somatic and germline mutations on the outcome of systemic mastocytosis.Blood advances · 2018Article
- Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions.Frontiers in pharmacology · 2016Review
- The need for United States-based guidelines for myeloproliferative neoplasms.Journal of the National Comprehensive Cancer Network : JNCCN · 2015Article
- Primary mast cell disorders in children.Current allergy and asthma reports · 2013Review
- Mastocytosis: update on pharmacotherapy and future directions.Expert opinion on pharmacotherapy · 2013Review
- Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis.Leukemia & lymphoma · 2013Article
- Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.American journal of hematology · 2013Article
- Immunology and clinical manifestations of non-clonal mast cell activation syndrome.Current allergy and asthma reports · 2013Review
- The class I PI3K/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic intervention.BMC veterinary research · 2012Article
- Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis.Cancer · 2011Review
- Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.International journal of laboratory hematology · 2010Review
- Recent advances in mast cell clonality and anaphylaxis.F1000 medicine reports · 2009Article
- Mastocytosis: a disease of the hematopoietic stem cell.Deutsches Arzteblatt international · 2008Article
- Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.British journal of pharmacology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mastocytosis is a disease characterized by pathological mast cell accumulation and activation in tissues. Most patients with mastocytosis exhibit the D816V point mutation in the tyrosine kinase domain of the transmembrane receptor protein Kit, leading to its constitutive activation in bone marrow or lesional skin tissue. Detection of a codon 816 c-kit mutation is included as a minor diagnostic criterion in the World Health Organization's diagnostic criteria for systemic mastocytosis. Determining mutational status of the c-kit gene also has pharmacogenomic implications in patients considered for investigational mast cell cytoreductive therapies. This article reviews diagnostic and therapeutic implications of c-kit mutations as well as other less common molecular abnormalities observed in mast cell disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.